SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-13-425280
Filing Date
2013-11-04
Accepted
2013-11-04 16:30:00
Documents
1
Group Members
CLARUS VENTURES II GP, L.P.CLARUS VENTURES II, LLCDENNIS HENNERKURT WHEELERMICHAEL STEINMETZNICHOLAS GALAKATOSNICHOLAS SIMONROBERT LIPTAK

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D d622002dsc13d.htm SC 13D 183763
  Complete submission text file 0001193125-13-425280.txt   185599
Mailing Address 7020 KIT CREEK ROAD SUITE 270 RESEARCH TRIANGLE PARK NC 27709
Business Address 7020 KIT CREEK ROAD SUITE 270 RESEARCH TRIANGLE PARK NC 27709 919-313-9650
AERIE PHARMACEUTICALS INC (Subject) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-87680 | Film No.: 131189486
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 101 MAIN STREET SUITE 1210 CAMBRIDGE MA 02142
Business Address 101 MAIN STREET SUITE 1210 CAMBRIDGE MA 02142 617-949-2200
Clarus Lifesciences II, L.P. (Filed by) CIK: 0001431443 (see all company filings)

IRS No.: 261856183 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D